Clinical Trials Logo

Fatty Liver clinical trials

View clinical trials related to Fatty Liver.

Filter by:

NCT ID: NCT03300661 Completed - Diet Modification Clinical Trials

Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine

SEELN
Start date: June 13, 2017
Phase: N/A
Study type: Interventional

The study is an open-label intervention non pharmacological Cohort Study without control arm in patients with Non Alcoholic Fatty Liver Disease (NAFLD) and in healthy subjects. The intervention in patients with NAFLD is educational, providing personalized suggestions to improve diet and physical activity; the intervention in healthy subjects is educational, providing general suggestions to improve diet and physical activity.

NCT ID: NCT03294850 Completed - Clinical trials for NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease

Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery

BARI
Start date: July 18, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.

NCT ID: NCT03289897 Completed - Metabolic Syndrome Clinical Trials

Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan

RADIcAL1
Start date: September 5, 2017
Phase: N/A
Study type: Interventional

A multi-centre randomised controlled trial to determine the implementation and health care cost of LiverMultiScan vs. routine methodical assessment (standard care) of Non-alcoholic fatty liver disease (NAFLD) across several European countries.

NCT ID: NCT03276039 Completed - Clinical trials for Non Alcoholic Fatty Liver Disease

Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus

Start date: April 15, 2014
Phase: N/A
Study type: Observational

This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.

NCT ID: NCT03261739 Completed - NAFLD Clinical Trials

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Start date: August 28, 2017
Phase: Phase 1
Study type: Interventional

BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.

NCT ID: NCT03260543 Completed - Clinical trials for Fatty Liver, Nonalcoholic

Efficacy and Safety of Fermented Ginseng Powder on Liver Function

Start date: July 2016
Phase: N/A
Study type: Interventional

This study was conducted to investigate the effects of daily supplementation of fermented ginseng powder on improvement of Liver function.

NCT ID: NCT03256526 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

6-week Safety and PD Study in Adults With NAFLD

Start date: September 27, 2017
Phase: Phase 2
Study type: Interventional

IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE

NCT ID: NCT03250572 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among NAFLD Patients

Start date: June 2015
Phase: N/A
Study type: Observational

This study was designed to assess the relation between serum ferritin and hepatic fibrosis in patients with NAFLD. It included 83 patients with NAFLD with or without hepatic fibrosis, in addition to 30 healthy subjects included as controls. Measurement of serum ferritin and its correlation with steatosis and fibrosis was done.

NCT ID: NCT03248882 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Start date: August 22, 2017
Phase: Phase 2
Study type: Interventional

Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT ID: NCT03245606 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non Alcoholic Fatty Liver Disease

FibroMR
Start date: December 7, 2017
Phase:
Study type: Observational

The main objective is to compare the accuracy of transient elastography taking into account liver steatosis determined by MRI, to liver biopsy for the diagnosis of liver fibrosis ≥F2 in patient with NAFLD.